European citizens have questions about the COVID-19 vaccines. Are they safe? Will they work? What about side effects? Answers to those questions are emerging, in part due to the efforts of the European Medicines Agency.

European citizens with rare diseases are struggling to maintain treatment during the COVID-19 pandemic, a new report explains.

Patients need a more meaningful role in decisions about the value of medications, a new report from the Global Alliance for Patient Access explains.

Effectively treating rheumatic and musculoskeletal diseases doesn’t just serve patients. It also benefits Europe’s workplaces.

The COVID-19 pandemic has made one point clear for advocates: Health technology assessments across Europe could work better and more efficiently.

Reaching consensus is a challenge for any community, and the global health care community is no exception.

According to new research from the World Health Organization, the treatment and prevention of non-communicable diseases have been “severely disrupted” since the pandemic began.

Los lideres y advocates de pacientes en América Latina están explorando como las políticas inteligentes pueden fomentar la innovación y proteger el acceso de los pacientes durante COVID-19.

Patient advocates across Latin America are exploring how smart policy can encourage innovation and protect patient access during COVID-19.

Last month patient groups and Members of the European Parliament pledged to “leave no-one behind” in their response to the COVID-19 pandemic.